AB-FUBINACA
AB-FUBINACA is a laboratory-made synthetic cannabinoid receptor agonist developed to activate the brain’s cannabinoid receptors. AB-FUBINACA (Correctly named AMB-FUBINACA using EUDA nomenclature, however this name is erroneously associated with MMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported.
